VacZine Analytics  
MarketVIEW: malaria vaccines

Updated: November 2011

Malaria (Plasmodium sp), a mosquito borne parasitic disease, is a major global killer with an estimated 863,000 deaths in 2008 (World Malaria Report). Currently half the world’s population is at risk with vulnerable groups such as young children, pregnant women and the HIV infected of particular concern. Although prevention and treatment paradigms to control malaria have been in place for many years these are dogged by numerous issues such as pathogen resistance, intervention availability and cost; particularly in Sub-Saharan Africa.

The prospect of a malaria vaccine is appealing because large-scale mass vaccination (as conducted with other diseases) could be implemented in Africa and make a significant impact. GSK Biologicals is developing Mosquirix (RTS, S) in Phase III studies across Africa. Although the vaccine has relatively low efficacy (~40-50%) in preventing clinical episodes it is a major step forward for the industry and is prompting other entities to pursue second generation approaches. RTS,S could be available in 2015/2016.

This MarketVIEW product gives a comprehensive vaccine value ($USD/volume doses 000s) forecast of Malaria vaccines until 2030. The model includes LO/BASE/HI forecast scenarios so the user can visualize the commercial impact of differing efficacy scenarios.


To order please contact your region account manager, buy "on-line" or order direct at:

VAMV017 Click here>>
Discounted option:
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. For UK orders VAT will be added at 20%. Please review the TERMS and CONDITIONS of purchase.

Return to main list>> Questions about this report?

© 2011 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains